Hanmi Surprises Again, Signing Big Diabetes Deal With Sanofi

South Korea's Hanmi Pharmaceutical is making the history books. Following its record-setting agreements with Lilly and Boehringer Ingelheim earlier this year, it has now inked a substantially bigger licensing out pact worth up to €3.9bn with Sanofi for its diabetes Quantum Project. While the deal will buoy the portfolio of the leading global diabetes player, it offers no quick fix, analysts caution.